Chronic Infusion of Atrial Natriuretic Peptide Attenuates Pulmonary Vascular Remodelling in Rats

1990 ◽  
Vol 79 (s23) ◽  
pp. 3P-3P
Author(s):  
RJD Winter ◽  
L Zhao ◽  
T Krausz ◽  
JMB Hughes
Keyword(s):  
Atrial Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Vascular Remodelling ◽  
Chronic Infusion ◽  
Pulmonary Vascular Remodelling ◽  
Atrial Natriuretic

Effects of the Neutral Endopeptidase Inhibitor, SCH 42495, on the Cardiovascular Remodelling Secondary to Chronic Hypoxia in Rats

1994 ◽  
Vol 87 (1) ◽  
pp. 109-114 ◽  
Author(s):  
J. S. Thompson ◽  
W. Sheedy ◽  
A. H. Morice
Keyword(s):  
Atrial Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Chronic Hypoxia ◽  
Neutral Endopeptidase ◽  
Pulmonary Vasculature ◽  
Vascular Remodelling ◽  
Plasma Atrial Natriuretic Peptide ◽  
And Control ◽  
Pulmonary Vascular Remodelling ◽  
Atrial Natriuretic

1. We have investigated the effects of inhibition of neutral endopeptidase on the cardiovascular remodelling secondary to chronic hypoxia in rats using a novel neutral endopeptidase inhibitor, SCH 42495. 2. Rats were divided into four groups, two of which were maintained in a normobaric, hypoxic chamber (10% O2) and two in room air. Animals received either neutral endopeptidase inhibitor, SCH 42495 (30 mg/kg), or aqueous methyl cellulose vehicle (0.4%) twice daily by oral gavage. 3. At 1, 3, 7, 10 and 14 days, animals (n = 4 per group for days 1, 3, 7 and 14, and n =8 for day 10) were killed. Hearts were dissected and weighed for determination of ventricular ratios, lungs were perfused with formol saline for histological examination of the pulmonary vasculature, and blood was collected for measurement of plasma atrial natriuretic peptide level. 4. Treatment with SCH 42495 caused a significant reduction in the pulmonary vascular remodelling and ventricular hypertrophy in hypoxic rats after 10 days. Plasma atrial natriuretic peptide levels were significantly elevated in both SCH 42495-treated and control hypoxic animals (n = 8) after 10 days when compared with the normoxic groups. However, there was no difference in plasma ANP levels between SCH 42495-treated and control chronic hypoxic groups at day 10. 5. Treatment with SCH 42495 leads to a decrease in cardiovascular remodelling secondary to chronic hypoxia in rats. A local action of atrial natriuretic peptide within the pulmonary vasculature may be responsible for this effect. Modulation of atrial natriuretic peptide may have therapeutic potential in the management of conditions characterized by pulmonary hypertension and pulmonary vascular remodelling.

Effects of continuous infusion of atrial natriuretic peptide on the pulmonary hypertension induced by chronic hypoxia in rats

1991 ◽  
Vol 81 (3) ◽  
pp. 379-385 ◽  
Author(s):  
L. Zhao ◽  
R. J. D. Winter ◽  
T. Krausz ◽  
J. M. B. Hughes
Keyword(s):  
Pulmonary Hypertension ◽  
Pulmonary Artery ◽  
Atrial Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Pulmonary Artery Pressure ◽  
Chronic Hypoxia ◽  
Systemic Blood Pressure ◽  
Artery Pressure ◽  
Pulmonary Vascular Remodelling ◽  
Atrial Natriuretic

1. The effects of the continuous infusion of atrial natriuretic peptide on the development of pulmonary hypertension were studied in rats exposed to chronic hypoxia. 2. Continuous intravenous infusion of two doses of synthetic rat atrial natriuretic peptide, 300 ng/h per rat (0.10 pmol/h per rat) and 800 ng/h per rat (0.28 pmol/h per rat), attenuated the development of pulmonary hypertension in rats exposed to chronic hypoxia (fractional concentration of oxygen in inspired air = 10%) for 7 days: (i) the pulmonary artery pressure (mean ± sd) in the vehicle-treated hypoxic group was 45 ± 6 mmHg compared with 28 ± 6 mmHg in the vehicle-treated normotoxic group (n = 8, P < 0.001); (ii) treatment with atrial natriuretic peptide in normoxia did not alter the pulmonary artery pressure, systemic blood pressure or heart rate; (iii) treatment with atrial natriuretic peptide in hypoxia resulted in a lower pulmonary artery pressure in the group treated with 800 ng of atrial natriuretic peptide/h per rat (38 ± 8 mmHg, P < 0.05 compared with the vehicle-treated hypoxic group) without affecting the systemic blood pressure or heart rate. 3. Chronic hypoxia resulted in an extension of vascular smooth muscle towards the periphery of the lung with the development of muscle in normally non-muscularized vessels (remodelling). Quantitative assessment of the small pulmonary vessels (external diameter 25–55 μm) showed that atrial natriuretic peptide treatment reduced pulmonary vascular remodelling in hypoxia (the percentage of thick-walled vessels in the peripheral lung hypoxic vehicle-treated group was 25 ± 6 compared with 19 ± 4 in the group given 300 ng of atrial natriuretic peptide/h per rat and 17 ± 7 in the group given 800 ng of atrial natriuretic peptide/h per rat, means ± sd, both P < 0.01 compared with the vehicle-treated normoxic group). 4. These data show that infusion of synthetic atrial natriuretic peptide attenuated the pulmonary vascular remodelling and associated pulmonary hypertension produced by chronic hypoxia.

Synthesis and secretion of atrial natriuretic peptide by BON cells: Stimulation by PMA and cGMP

2001 ◽  
Vol 120 (5) ◽  
pp. A682-A682
Author(s):  
W GOWERJR ◽  
G CARTER ◽  
C LANDON ◽  
W GOWERIII ◽  
J DIETZ ◽  
...  
Keyword(s):  
Atrial Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Bon Cells ◽  
Atrial Natriuretic

Hemodynamic and renal effects following bolus injection of atrial natriuretic peptide (α-hANP) in normal subjects

1988 ◽  
Vol 117 (4_Suppl) ◽  
pp. S235-S236
Author(s):  
G. MÜLLER-ESCH ◽  
J. POTRATZ ◽  
W. KLINGLER ◽  
R. GERZER ◽  
R. LAWRENZ ◽  
...  
Keyword(s):  
Atrial Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Bolus Injection ◽  
Normal Subjects ◽  
Renal Effects ◽  
Atrial Natriuretic

Atrial natriuretic peptide in liver cirrhosis. Renal and endocrine effects

1987 ◽  
Vol 116 (3_Suppl) ◽  
pp. S160-S161
Author(s):  
M. KIRSCHNER ◽  
G. BRABANT ◽  
H. JÜPPNER ◽  
E. u. F. W. SCHMIDT ◽  
R. D. HESCH
Keyword(s):  
Liver Cirrhosis ◽  
Atrial Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Endocrine Effects ◽  
Atrial Natriuretic
Sign in / Sign up

Export Citation Format

Share Document